STOCK TITAN

Addex Therapeutics Ltd - ADXN STOCK NEWS

Welcome to our dedicated news page for Addex Therapeutics (Ticker: ADXN), a resource for investors and traders seeking the latest updates and insights on Addex Therapeutics.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Addex Therapeutics's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Addex Therapeutics's position in the market.

Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.7%
Tags
none
Addex Therapeutics Ltd

Nasdaq:ADXN

ADXN Rankings

ADXN Stock Data

24.20M
48.22M
18.49%
0.82%
Pharmaceutical Preparation Manufacturing
Manufacturing
Link
Switzerland
Plan Les Ouates

About ADXN

addex therapeutics is pioneering discovery and development of an emerging class of oral small molecule drugs, called allosteric modulators, which can be exquisitely selective for their intended target and confer significant therapeutic advantages over conventional “orthosteric” small molecule or biological drugs. the company uses its proprietary discovery platform to address receptors and other proteins that have been undruggable for conventional drug discovery methods, including g-protein coupled receptors (gpcrs), receptor tyrosine kinases (rtks) and cytokine receptors, such as the tnf receptor superfamily. many such targets have been widely recognized as attractive for modulation of important diseases with unmet medical needs, but have remained inaccessible to small molecule drug discovery. the company’s two lead products are: dipraglurant (adx48621), an mglur5 negative allosteric modulator, or nam, which reduced parkinson’s disease levodopa-induced dyskinesia (pd-lid) in a phase ii